Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Jun;63(6):730–736. doi: 10.1136/ard.2003.007245

Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies

G Espinosa 1, S Bucciarelli 1, R Cervera 1, M Lozano 1, J Reverter 1, G de la Red 1, V Gil 1, M Ingelmo 1, J Font 1, R Asherson 1
PMCID: PMC1755024  PMID: 15140782

Abstract

Objective: To analyse the clinical and laboratory features of patients with thrombotic microangiopathic haemolytic anaemia (TMHA) associated with antiphospholipid antibodies (aPL).

Methods: A computer assisted (PubMed) search of the literature was performed to identify all cases of TMHA associated with aPL from 1983 to December 2002.

Results: 46 patients (36 female) with a mean (SD) age at presentation of TMHA of 34 (15) years were reviewed. Twenty eight (61%) patients had primary antiphospholipid syndrome (APS). TMHA was the first clinical manifestation of APS in 26 (57%) patients. The clinical presentations were haemolytic-uraemic syndrome (26%), catastrophic APS (23%), acute renal failure (15%), malignant hypertension (13%), thrombotic thrombocytopenic purpura (13%), and HELLP (haemolysis, elevated liver enzymes, and low platelet count in association with eclampsia) syndrome (4%). Lupus anticoagulant was detected in 86% of the episodes of TMHA, and positive anticardiolipin antibodies titres in 89%. Steroids were the most common treatment (69% of episodes), followed by plasma exchange (PE) (62%), anticoagulant or antithrombotic agents (48%), immunosuppressive agents (29%), and immunoglobulins (12%). Recovery occurred in only 10/29 (34%) episodes treated with steroids, and in 19/27 (70%) episodes treated with PE. Death occurred in 10/46 (22%) patients.

Conclusions: The results emphasise the need for systematic screening for aPL in all patients with clinical and laboratory features of TMHA. The existence of TMHA in association with an APS forces one to rule out the presence of the catastrophic variant of this syndrome. PE is indicated as a first line of treatment for all patients with TMHA associated with aPL.

Full Text

The Full Text of this article is available as a PDF (100.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardiles L. G., Olavarría F., Elgueta M., Moya P., Mezzano S. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenic role. Nephron. 1998;78(3):278–283. doi: 10.1159/000044936. [DOI] [PubMed] [Google Scholar]
  2. Asherson R. A., Cervera R., Piette J. C., Shoenfeld Y., Espinosa G., Petri M. A., Lim E., Lau T. C., Gurjal A., Jedryka-Góral A. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001 Nov;80(6):355–377. doi: 10.1097/00005792-200111000-00002. [DOI] [PubMed] [Google Scholar]
  3. Asherson R. A. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992 Apr;19(4):508–512. [PubMed] [Google Scholar]
  4. Baid S., Pascual M., Williams W. W., Jr, Tolkoff-Rubin N., Johnson S. M., Collins B., Chung R. T., Delmonico F. L., Cosimi A. B., Colvin R. B. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999 Jan;10(1):146–153. doi: 10.1681/ASN.V101146. [DOI] [PubMed] [Google Scholar]
  5. Becquemont L., Thervet E., Rondeau E., Lacave R., Mougenot B., Sraer J. D. Systemic and renal fibrinolytic activity in a patient with anticardiolipin syndrome and renal thrombotic microangiopathy. Am J Nephrol. 1990;10(3):254–258. doi: 10.1159/000168093. [DOI] [PubMed] [Google Scholar]
  6. Bendon R. W., Wilson J., Getahun B., van der Bel-Kahn J. A maternal death due to thrombotic disease associated with anticardiolipin antibody. Arch Pathol Lab Med. 1987 Apr;111(4):370–372. [PubMed] [Google Scholar]
  7. Brandt J. T., Triplett D. A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995 Oct;74(4):1185–1190. [PubMed] [Google Scholar]
  8. Cacoub P., Wechsler B., Piette J. C., Beaufils H., Herreman G., Bletry O., Godeau P. Malignant hypertension in antiphospholipid syndrome without overt lupus nephritis. Clin Exp Rheumatol. 1993 Sep-Oct;11(5):479–485. [PubMed] [Google Scholar]
  9. Cerveny K. C., Sawitzke A. D. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus. 1999;8(6):477–481. doi: 10.1177/096120339900800613. [DOI] [PubMed] [Google Scholar]
  10. Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Doménech I., Aydintug A. O., Jedryka-Góral A., de Ramón E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar;72(2):113–124. [PubMed] [Google Scholar]
  11. Chew C. G., Bannister K. M., Mathew T. H., Russ G., Seymour A. Thrombotic microangiopathy related to anticardiolipin antibody in a renal allograft. Nephrol Dial Transplant. 1999 Feb;14(2):436–438. doi: 10.1093/ndt/14.2.436. [DOI] [PubMed] [Google Scholar]
  12. Dang C. T., Magid M. S., Weksler B., Chadburn A., Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood. 1999 Feb 15;93(4):1264–1270. [PubMed] [Google Scholar]
  13. Descombes E., Droz D., Drouet L., Grünfeld J. P., Lesavre P. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997 Sep;76(5):355–368. doi: 10.1097/00005792-199709000-00003. [DOI] [PubMed] [Google Scholar]
  14. Diez-Ewald M., Torres-Guerra E., Vizcaíno G., Arteaga-Vizcaíno M. Platelet function in patients with lupus anticoagulant and thrombosis. Invest Clin. 1995 Mar;36(1):13–21. [PubMed] [Google Scholar]
  15. Durand J. M., Lefevre P., Kaplanski G., Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991 Dec;18(12):1916–1918. [PubMed] [Google Scholar]
  16. Elliott M. A., Nichols W. L. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc. 2001 Nov;76(11):1154–1162. doi: 10.4065/76.11.1154. [DOI] [PubMed] [Google Scholar]
  17. Farrugia E., Torres V. E., Gastineau D., Michet C. J., Holley K. E. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis. 1992 Nov;20(5):463–471. doi: 10.1016/s0272-6386(12)70258-5. [DOI] [PubMed] [Google Scholar]
  18. Frampton G., Hicks J., Cameron J. S. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int. 1991 Jun;39(6):1225–1231. doi: 10.1038/ki.1991.155. [DOI] [PubMed] [Google Scholar]
  19. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P. A., Brenner B., Krause M., Scharrer I., Aumann V., Mittler U. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998 Nov 26;339(22):1578–1584. doi: 10.1056/NEJM199811263392202. [DOI] [PubMed] [Google Scholar]
  20. Gatenby P. A., Smith H., Kirwan P., Lauer C. S. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. A case report and review of relationship. J Rheumatol. 1981 May-Jun;8(3):504–508. [PubMed] [Google Scholar]
  21. George J. N. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000 Aug 15;96(4):1223–1229. [PubMed] [Google Scholar]
  22. Gherman R. B., Tramont J., Connito D. J. Postpartum hemolytic-uremic syndrome associated with lupus anticoagulant. A case report. J Reprod Med. 1999 May;44(5):471–474. [PubMed] [Google Scholar]
  23. Glueck H. I., Kant K. S., Weiss M. A., Pollak V. E., Miller M. A., Coots M. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med. 1985 Aug;145(8):1389–1395. [PubMed] [Google Scholar]
  24. Goodnough L. T., Brecher M. E., Kanter M. H., AuBuchon J. P. Transfusion medicine. First of two parts--blood transfusion. N Engl J Med. 1999 Feb 11;340(6):438–447. doi: 10.1056/NEJM199902113400606. [DOI] [PubMed] [Google Scholar]
  25. Grinberg A. R., Heller P. G., Correa G., Sarano J. F., Molinas F. C., Nicastro M. A., Alvarez C. L. Síndrome antifosfolipídico catastrófico. Comunicación de dos formas de presentación. Medicina (B Aires) 1999;59(6):743–746. [PubMed] [Google Scholar]
  26. Hashimoto K., Tabata N., Fujisawa R., Matsumura H., Miyazawa M. Induction of microthrombotic thrombocytopenia in normal mice by transferring a platelet-reactive, monoclonal anti-gp70 autoantibody established from MRL/lpr mice: an autoimmune model of thrombotic thrombocytopenic purpura. Clin Exp Immunol. 2000 Jan;119(1):47–56. doi: 10.1046/j.1365-2249.2000.01116.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hess D. C., Sethi K., Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992 Sep;19(9):1474–1478. [PubMed] [Google Scholar]
  28. Heyl W., Handt S., Reister F., Gehlen J., Schröder W., Mittermayer C., Rath W. Elevated soluble adhesion molecules in women with pre-eclampsia. Do cytokines like tumour necrosis factor-alpha and interleukin-1beta cause endothelial activation. Eur J Obstet Gynecol Reprod Biol. 1999 Sep;86(1):35–41. doi: 10.1016/s0301-2115(99)00042-1. [DOI] [PubMed] [Google Scholar]
  29. Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725–1725. doi: 10.1002/art.1780400928. [DOI] [PubMed] [Google Scholar]
  30. Huang J. J., Chen M. W., Sung J. M., Lan R. R., Wang M. C., Chen F. F. Postpartum haemolytic uraemic syndrome associated with antiphospholipid antibody. Nephrol Dial Transplant. 1998 Jan;13(1):182–186. doi: 10.1093/ndt/13.1.182. [DOI] [PubMed] [Google Scholar]
  31. Hughson M. D., Nadasdy T., McCarty G. A., Sholer C., Min K. W., Silva F. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis. 1992 Aug;20(2):150–158. doi: 10.1016/s0272-6386(12)80543-9. [DOI] [PubMed] [Google Scholar]
  32. Itoh Y., Sekine H., Hosono O., Takeuchi T., Koide J., Takano M., Abe T. Thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus: clinical significance of anti-platelet antibodies. Clin Immunol Immunopathol. 1990 Oct;57(1):125–136. doi: 10.1016/0090-1229(90)90028-o. [DOI] [PubMed] [Google Scholar]
  33. Jain R., Chartash E., Susin M., Furie R. Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum. 1994 Dec;24(3):173–182. doi: 10.1016/0049-0172(94)90073-6. [DOI] [PubMed] [Google Scholar]
  34. Kant K. S., Pollak V. E., Weiss M. A., Glueck H. I., Miller A. N., Hess E. V. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore) 1981 Mar;60(2):71–86. doi: 10.1097/00005792-198103000-00001. [DOI] [PubMed] [Google Scholar]
  35. Kincaid-Smith P., Fairley K. F., Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med. 1988 Oct;68(258):795–815. [PubMed] [Google Scholar]
  36. Kniaz D., Eisenberg G. M., Elrad H., Johnson C. A., Valaitis J., Bregman H. Postpartum hemolytic uremic syndrome associated with antiphospholipid antibodies. A case report and review of the literature. Am J Nephrol. 1992;12(1-2):126–133. doi: 10.1159/000168432. [DOI] [PubMed] [Google Scholar]
  37. Kon S. P., Kwan J. T., Raftery M. J. Reversible renal failure due to the antiphospholipid antibody syndrome, pre-eclampsia and renal thrombotic microangiopathy. Clin Nephrol. 1995 Oct;44(4):271–273. [PubMed] [Google Scholar]
  38. Kupferminc M. J., Lee M. J., Green D., Peaceman A. M. Severe postpartum pulmonary, cardiac, and renal syndrome associated with antiphospholipid antibodies. Obstet Gynecol. 1994 May;83(5 Pt 2):806–807. [PubMed] [Google Scholar]
  39. Lacueva J., Enríquez R., Cabezuelo J. B., Arenas M. D., Teruel A., González C. Acute renal failure as first clinical manifestation of the primary antiphospholipid syndrome. Nephron. 1993;64(3):479–480. doi: 10.1159/000187378. [DOI] [PubMed] [Google Scholar]
  40. Lajoie G., Kumar S., Min K. W., Silva F. G. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases. Am J Surg Pathol. 1995 Sep;19(9):1021–1028. doi: 10.1097/00000478-199509000-00005. [DOI] [PubMed] [Google Scholar]
  41. Lip G. Y., Edmunds E., Hee F. L., Blann A. D., Beevers D. G. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens. 2001 Aug;14(8 Pt 1):823–828. doi: 10.1016/s0895-7061(01)02045-3. [DOI] [PubMed] [Google Scholar]
  42. Love P. E., Santoro S. A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990 May 1;112(9):682–698. doi: 10.7326/0003-4819-112-9-682. [DOI] [PubMed] [Google Scholar]
  43. Matsuda J., Sanaka T., Gohchi K., Matsui K., Uchida S., Matsumoto M., Fujimura Y. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease. Lupus. 2002;11(7):463–464. doi: 10.1191/0961203302lu230xx. [DOI] [PubMed] [Google Scholar]
  44. McLeod B. C., Sniecinski I., Ciavarella D., Owen H., Price T. H., Randels M. J., Smith J. W. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999 Mar;39(3):282–288. doi: 10.1046/j.1537-2995.1999.39399219285.x. [DOI] [PubMed] [Google Scholar]
  45. Meyrier A., Becquemont L., Weill B., Callard P., Rainfray M. Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron. 1991;59(3):493–496. doi: 10.1159/000186616. [DOI] [PubMed] [Google Scholar]
  46. Mitra D., Jaffe E. A., Weksler B., Hajjar K. A., Soderland C., Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood. 1997 Feb 15;89(4):1224–1234. [PubMed] [Google Scholar]
  47. Moake Joel L. Thrombotic microangiopathies. N Engl J Med. 2002 Aug 22;347(8):589–600. doi: 10.1056/NEJMra020528. [DOI] [PubMed] [Google Scholar]
  48. Montecucco C., Di Lauro M., Bobbio-Pallavicini E., Longhi M., Caporali R., De Gennaro F., Ascari E. Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol. 1987 Oct-Dec;5(4):355–358. [PubMed] [Google Scholar]
  49. Mori Yoshitaka, Wada Hideo, Gabazza Esteban C., Minami Nobuyuki, Nobori Tsutomu, Shiku Hiroshi, Yagi Hideo, Ishizashi Hiromichi, Matsumoto Masanori, Fujimura Yoshihiro. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002 May;42(5):572–580. doi: 10.1046/j.1537-2995.2002.00100.x. [DOI] [PubMed] [Google Scholar]
  50. Morita H., Suwa T., Daidoh H., Takeda N., Ishizuka T., Yasuda K. Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome. Am J Med Sci. 1996 Mar;311(3):148–151. doi: 10.1097/00000441-199603000-00009. [DOI] [PubMed] [Google Scholar]
  51. Mukai M., Ieko M., Atsumi T., Notoya A., Kohno M. Multiple thromboses in major arteries in a patient with antiphospholipid syndrome associated with excess of a large multimer of von Willebrand factor. Lupus. 2001;10(12):895–896. doi: 10.1191/096120301701548418. [DOI] [PubMed] [Google Scholar]
  52. Musa M. O., Nounou R., Sahovic E., Seth P., Qadi A., Aljurf M. Fulminant thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus and phospholipid autoantibodies. Eur J Haematol. 2000 Jun;64(6):433–435. doi: 10.1034/j.1600-0609.2000.9l125.x. [DOI] [PubMed] [Google Scholar]
  53. Musio F., Bohen E. M., Yuan C. M., Welch P. G. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998 Aug;28(1):1–19. doi: 10.1016/s0049-0172(98)80023-1. [DOI] [PubMed] [Google Scholar]
  54. Nakamura N., Shidara Y., Kawaguchi N., Azuma C., Mitsuda N., Onishi S., Yamaji K., Wada Y. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1488–1493. doi: 10.1006/bbrc.1994.2833. [DOI] [PubMed] [Google Scholar]
  55. Nesher G., Hanna V. E., Moore T. L., Hersh M., Osborn T. G. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum. 1994 Dec;24(3):165–172. doi: 10.1016/0049-0172(94)90072-8. [DOI] [PubMed] [Google Scholar]
  56. Neuwelt C. M., Daikh D. I., Linfoot J. A., Pfister D. A., Young R. G., Webb R. L., London S. S., Asherson R. A. Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum. 1997 Aug;40(8):1534–1539. doi: 10.1002/art.1780400823. [DOI] [PubMed] [Google Scholar]
  57. Nochy D., Daugas E., Droz D., Beaufils H., Grünfeld J. P., Piette J. C., Bariety J., Hill G. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999 Mar;10(3):507–518. doi: 10.1681/ASN.V103507. [DOI] [PubMed] [Google Scholar]
  58. Ornstein M. H., Rand J. H. An association between refractory HELLP syndrome and antiphospholipid antibodies during pregnancy; a report of 2 cases. J Rheumatol. 1994 Jul;21(7):1360–1364. [PubMed] [Google Scholar]
  59. Petras T., Rudolph B., Filler G., Zimmering M., Ditscherlein G., Loening S. A., Ehrich J. H. An adolescent with acute renal failure, thrombocytopenia and femoral vein thrombosis. Nephrol Dial Transplant. 1998 Feb;13(2):480–483. doi: 10.1093/oxfordjournals.ndt.a027852. [DOI] [PubMed] [Google Scholar]
  60. Ruggenenti P., Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin North Am. 1990 Feb;4(1):219–241. [PubMed] [Google Scholar]
  61. SYMMERS W. S. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J. 1952 Oct 25;2(4790):897–903. doi: 10.1136/bmj.2.4790.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Sakaguchi S., Kitazawa K., Watanabe M., Mukai K., Totsuka D., Shibata T., Sugisaki T. A case of primary antiphospholipid antibody syndrome with acute renal failure showing thrombotic microangiopathy. Am J Nephrol. 1999;19(5):594–598. doi: 10.1159/000013526. [DOI] [PubMed] [Google Scholar]
  63. Schinco P., Borchiellini A., Tamponi G., Montaruli B., Garis G., Bazzan M., Pannocchia A., Modena V., Pileri A. Lupus anticoagulant and thrombosis: role of von Willebrand factor multimeric forms. Clin Exp Rheumatol. 1997 Jan-Feb;15(1):5–10. [PubMed] [Google Scholar]
  64. Scully R. E., Mark E. J., McNeely W. F., Ebeling S. H., Phillips L. D. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1997. A 74-year-old man with progressive cough, dyspnea, and pleural thickening. N Engl J Med. 1997 Jun 26;336(26):1895–1903. doi: 10.1056/NEJM199706263362608. [DOI] [PubMed] [Google Scholar]
  65. Simantov R., LaSala J. M., Lo S. K., Gharavi A. E., Sammaritano L. R., Salmon J. E., Silverstein R. L. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995 Nov;96(5):2211–2219. doi: 10.1172/JCI118276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Sirvent A. E., Enriquez R., Antolin A., Cabezuelo J. B., Gonzalez C., Arenas M. D. Malignant hypertension and antiphospholipid syndrome. Nephron. 1996;73(2):368–369. doi: 10.1159/000189092. [DOI] [PubMed] [Google Scholar]
  67. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  68. Trent K., Neustater B. R., Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Am J Hematol. 1997 Feb;54(2):155–159. doi: 10.1002/(sici)1096-8652(199702)54:2<155::aid-ajh10>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  69. Tsai H. M., Lian E. C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998 Nov 26;339(22):1585–1594. doi: 10.1056/NEJM199811263392203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Veyradier A., Obert B., Houllier A., Meyer D., Girma J. P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001 Sep 15;98(6):1765–1772. doi: 10.1182/blood.v98.6.1765. [DOI] [PubMed] [Google Scholar]
  71. Vivaldi P., Andreotti C., Mazzon C., Pedrazzoli M. A "primitive" catastrophic antiphospholipid syndrome. Haematologica. 1994 Mar-Apr;79(2):173–176. [PubMed] [Google Scholar]
  72. Wilson W. A., Gharavi A. E., Koike T., Lockshin M. D., Branch D. W., Piette J. C., Brey R., Derksen R., Harris E. N., Hughes G. R. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul;42(7):1309–1311. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  73. Yamazaki Satoshi, Taki Masashi, Yasumuro Yoko, Takayama Shigenobu, Miyake Fumihiko, Fujimura Yoshihiro, Suzuki Yasuo. [Von Willebrand factor-cleaving protease activity in patients of collagen disease with antiphospholipid antibodies]. Rinsho Byori. 2002 Mar;50(3):301–307. [PubMed] [Google Scholar]
  74. Zakynthinos E. G., Vassilakopoulos T., Kontogianni D. D., Roussos C., Zakynthinos S. G. A role for transoesophageal echocardiography in the early diagnosis of catastrophic antiphospholipid syndrome. J Intern Med. 2000 Dec;248(6):519–524. doi: 10.1046/j.1365-2796.2000.00762.x. [DOI] [PubMed] [Google Scholar]
  75. do Sameiro Faria M., Mota C., Barbot J., Alvares S., Jardim H., Vilarinho A., Pereira E. Haemolytic uraemic syndrome, cardiomyopathy, cutaneous vasculopathy and anti-phospholipid activity. Nephrol Dial Transplant. 2000 Nov;15(11):1891–1892. doi: 10.1093/ndt/15.11.1891. [DOI] [PubMed] [Google Scholar]
  76. von Tempelhoff G. F., Heilmann L., Spanuth E., Kunzmann E., Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb Res. 2000 Nov 15;100(4):363–365. doi: 10.1016/s0049-3848(00)00312-1. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Web-only Tables]
annrheumd_63_6_730__index.html (1.5KB, html)
annrheumd_63_6_730__1.pdf (82.2KB, pdf)
annrheumd_63_6_730__2.pdf (54.3KB, pdf)

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES